Archives

Perfusfind S.L.

Abstract Objectives To describe outcomes in patients who received venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock and to evaluate outcomes following programmatic changes. Design A retrospective cohort study. Setting..

Perfusfind S.L.

Abstract OBJECTIVES Cardiogenic shock is still a major clinical challenge, despite the available devices. We developed a minimally invasive, transapical dual-lumened cannula, which can provide antegrade circulatory support and unloading..

Perfusfind S.L.

Abstract Background: Severe poisoning can lead to catastrophic cardiovascular collapse, often progressing to multiorgan failure and death. While intensive supportive care and pharmacological intervention remain the cornerstone of management, cases of..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is widely recognized as a life-saving measure. The use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) is on the rise, serving as an effective mechanical..

Perfusfind S.L.

Abstract Background A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using..

Perfusfind S.L.

Abstract Background A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using..

Perfusfind S.L.

Abstract Introduction Extracorporeal membrane oxygenation (ECMO) is an established therapy that supports a patient in respiratory or cardiopulmonary failure to recovery, transplant, or durable mechanical support. Prompt referral by the..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Background The microaxial flow pump (mAFP) improves survival in selected patients with ST-segment elevation myocardial infarction–induced cardiogenic shock (STEMI-CS). Understanding the impact on cardiac output (CO), cardiac power output..

Perfusfind S.L.

Abstract We investigated echocardiographic and hemodynamic effects of intraaortic balloon pump (IABP) in 26 patients with cardiogenic shock on veno-arterial membrane oxygenation (VA ECMO). Our study demonstrated an 8.1% increase..

Perfusfind S.L.

Abstract Objective To investigate the factors contributing to the "ECMO gap," the discrepancy between successful weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and survival to hospital discharge, using different definitions..

Perfusfind S.L.

Abstract Objective The use of an intra-aortic balloon pump (IABP) has been suggested to unload the left ventricle while on venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock (CS), leading..

Perfusfind S.L.

Abstract While iterative developments have improved outcomes of patients with myocardial infarction, mortality in patients with acute myocardial infarction cardiogenic shock (AMI-CS) remains stubbornly high. Several promising treatments have ultimately..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) in acute myocardial infarction (AMI) is a life-threatening syndrome characterized by systemic hypoperfusion that can quickly progress to multiorgan failure and death. Various devices and configurations..

Perfusfind S.L.

Abstract Sepsis-induced cardiomyopathy is a severe complication seen in patients with refractory septic shock, characterized by cardiac dysfunction due to an overwhelming inflammatory response secondary to infection. Despite its reversible..

Perfusfind S.L.

Abstract Background Clinical evidence regarding predictors of successful weaning from mechanical circulatory support (MCS) is lacking. This study aimed to create a simple risk score to predict successful weaning from..

Perfusfind S.L.

Abstract The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support (MCS) is a common treatment in patients with cardiogenic shock (CS) but is associated with high..

Perfusfind S.L.

Abstract Background Approximately 6000 intensive care units (ICUs) in the United States maintain extracorporeal membrane oxygenation (ECMO) programs.1 Patients who require ECMO are among the most critically ill in the ICU...

Perfusfind S.L.

Abstract PROFOUND HYPOTENSION AND end-organ hypoperfusion are most often the consequence of inadequate systemic blood flow from primary cardiac failure (cardiogenic shock) or hemorrhage (hemorrhagic shock). However, profound hypotension may..

Perfusfind S.L.

Abstract The use of intra-aortic balloon pump (IABP) alongside venoarterial extracorporeal membrane oxygenation (VA-ECMO) in critically ill patients presenting refractory cardiogenic shock raises questions regarding its impact on organs perfusion...

Perfusfind S.L.

Abstract Cardiogenic shock (CS) in patients with structural heart disease (SHD) and severe valvular abnormalities poses unique challenges to traditional mechanical circulatory support (MCS) strategies, such as intra-aortic balloon pumps..

Perfusfind S.L.

Abstract This study conducts an in-vitro experiment using a mock circulation system that mimics human circulation to assess the veno-arterial extracorporeal membrane oxygenation (ECMO) system. This study aims to compare the hemodynamic..

Perfusfind S.L.

Introduction Profound hypotension and end-organ hypoperfusion is most often a consequence of inadequate systemic blood flow from primary cardiac failure (cardiogenic shock) or hemorrhage (hemorrhagic shock). However, profound hypotension may..

Perfusfind S.L.

Abstract Acute poisoning may lead to life-threatening conditions that require advanced life support, such as extracorporeal membrane oxygenation (ECMO). Data about the use of ECMO in intoxications and overdose are..

Perfusfind S.L.

Abstract Background Veno-Arterial Extracorporeal Life Support (VA ECMO) is a critical intervention for patients with cardiogenic shock, serving as bridge to recovery, transplantation, or long-term therapies. The complexity of VA..

Perfusfind S.L.

Abstract Background Preliminary evidence from small, single-center studies suggests levosimendan may improve the likelihood of successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning in patients with cardiogenic shock. However, the literature..

Perfusfind S.L.

Abstract Sickle cell disease (SCD) is associated with substantial morbidity and early mortality in afflicted adults. Cardiopulmonary complications that occur at increased frequency in SCD such as pulmonary embolism, pulmonary..

Perfusfind S.L.

Abstract Venopulmonary ECMO (VP ECMO) is an advanced support strategy for patients with severe respiratory failure and right ventricular (RV) dysfunction, providing pulmonary protection by oxygenating blood and unloading the..

Perfusfind S.L.

Abstract Background The impact of intra-aortic balloon pump (IABP) on survival and successful bridging to heart replacement therapies (HRT) in patients with heart failure–cardiogenic shock (HF-CS) remains unclear. Objectives The..

Perfusfind S.L.

Abstract Background The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) as a cardiocirculatory support has tremendously increased in critically ill patients. Although fluid therapy is an essential component of the..